# UNICANCER

Source: https://onco.cc/companies/unicancer/  
OnCo record `unicancer` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UNICANCER is the network of France's comprehensive cancer centres and its academic trials sponsor.

## Summary

UNICANCER, based in Paris, is the network of France's comprehensive cancer centres and its academic trials sponsor, federating eighteen centres including Gustave Roussy, Institut Curie, the Institut du Cancer de Montpellier and Centre Jean Perrin. It runs the UCBG breast group, the PRODIGE gastrointestinal group whose PRODIGE 7 trial tested HIPEC, the GETUG genitourinary group and the ESME real-world database, with Christophe Le Tourneau, Jean-Yves Blay and Thomas Bachelot among the people linked. OnCo connects it to colorectal and triple-negative breast cancer, to real-world evidence, and to ideas such as a publicly held library of investigational drugs for academic combination trials and one standing umbrella trial for all rare cancers in a country. Slow enrolment is the bottleneck it exists to solve. Its PRODIGE, UCBG and ESME programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: Unicancer; Fédération Nationale des Centres de Lutte Contre le Cancer; FNCLCC
- Tags: cooperative-group
- HQ: Paris
- Type: cooperative-group
- Website: https://www.unicancer.fr

## Notes

- PRODIGE GI trials
- UCBG breast trials
- ESME real-world data

## Sources

- Official website: https://www.unicancer.fr
- UNICANCER: the centres: https://www.unicancer.fr/en/the-centres/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/)
- institutions: [Centre Antoine Lacassagne](https://onco.cc/institutions/centre-antoine-lacassagne/), [Centre Eugène Marquis](https://onco.cc/institutions/centre-eugene-marquis/), [Centre François Baclesse](https://onco.cc/institutions/centre-francois-baclesse/), [Centre Georges-François Leclerc](https://onco.cc/institutions/centre-georges-francois-leclerc/), [Centre Henri Becquerel](https://onco.cc/institutions/centre-henri-becquerel/), [Centre Jean Perrin](https://onco.cc/institutions/centre-jean-perrin/), [Centre Léon Bérard](https://onco.cc/institutions/centre-leon-berard/), [Centre Oscar Lambret](https://onco.cc/institutions/centre-oscar-lambret/), [Fondation ARC pour la recherche sur le cancer](https://onco.cc/institutions/fondation-arc/), [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/), [Haute Autorité de Santé](https://onco.cc/institutions/has-france/), [Institut Bergonié](https://onco.cc/institutions/institut-bergonie/), [Institut Curie](https://onco.cc/institutions/institut-curie/), [Institut de Cancérologie de l'Ouest (ICO)](https://onco.cc/institutions/ico-angers-nantes/), [Institut de Cancérologie de Lorraine](https://onco.cc/institutions/institut-de-cancerologie-de-lorraine/), [Institut du Cancer de Montpellier (ICM)](https://onco.cc/institutions/icm-montpellier/), [Institut Godinot](https://onco.cc/institutions/institut-godinot/), [Institut National du Cancer](https://onco.cc/institutions/inca/), [Institut Paoli-Calmettes](https://onco.cc/institutions/institut-paoli-calmettes/), [Institut Strauss](https://onco.cc/institutions/institut-strauss/), [IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)](https://onco.cc/institutions/iuct-oncopole/), [Ligue nationale contre le cancer](https://onco.cc/institutions/ligue-contre-le-cancer/)
- terms: [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- trials: [Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery](https://onco.cc/trials/nct05973864/), [Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.](https://onco.cc/trials/nct07192068/), [Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme](https://onco.cc/trials/nct06475352/), [Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI](https://onco.cc/trials/nct06333314/), [GETUG 13](https://onco.cc/trials/getug-13/), [GETUG-AFU 15](https://onco.cc/trials/getug-afu-15/), [GETUG-AFU 16](https://onco.cc/trials/getug-afu-16/), [GETUG-AFU 17](https://onco.cc/trials/getug-afu-17/), [Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse](https://onco.cc/trials/nct00055731/), [Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer](https://onco.cc/trials/nct07745296/), [Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease](https://onco.cc/trials/nct07284394/), [Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients](https://onco.cc/trials/nct03643133/), [PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct03774732/), [PEACE-1](https://onco.cc/trials/peace-1/), [Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC](https://onco.cc/trials/nct06078384/), [Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test](https://onco.cc/trials/nct07340567/), [Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer](https://onco.cc/trials/nct06606730/), [PRODIGE 23](https://onco.cc/trials/prodige-23/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [PRODIGE 4 / ACCORD 11](https://onco.cc/trials/prodige-4-accord-11/), [PRODIGE 7](https://onco.cc/trials/prodige-7/), [Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer](https://onco.cc/trials/nct05552001/), [Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer](https://onco.cc/trials/nct00630032/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [SAFIR-ABC10](https://onco.cc/trials/safir-abc10/), [SEVILLA](https://onco.cc/trials/sevilla/), [Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO](https://onco.cc/trials/nct05078047/), [Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old](https://onco.cc/trials/nct07118800/), [Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases](https://onco.cc/trials/nct07359456/), [Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers](https://onco.cc/trials/nct07437287/), [Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo](https://onco.cc/trials/nct07151586/), [Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer](https://onco.cc/trials/nct00104741/)
- people: [Anthony Gonçalves](https://onco.cc/people/anthony-goncalves/), [Christophe Le Tourneau](https://onco.cc/people/christophe-le-tourneau/), [Jean-Yves Blay](https://onco.cc/people/jean-yves-blay/), [Thomas Bachelot](https://onco.cc/people/thomas-bachelot/)
- key papers: [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)](https://onco.cc/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/), [Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial](https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/), [Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23)](https://onco.cc/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- bottlenecks: [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- ideas: [A publicly held library of investigational drugs available for academic combination trials](https://onco.cc/ideas/idea-tr2-public-combination-formulary/), [One standing umbrella trial for all rare cancers in a country](https://onco.cc/ideas/idea-bio2-rare-cancer-umbrella-platform/)
- companies: [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/), [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/)

---
JSON: https://onco.cc/api/v1/entities/unicancer.json